Antifungal Interventions and Clinical Outcomes: A Review
Abstract
Fungal infections pose a significant risk to public health since they are linked to high rates of illness and death, particularly in immunocompromised individuals. Therapy is difficult because there are few antifungal drugs available and many of them are harmful. Fungi have also evolved defence mechanisms to fight these drugs. This article overlooks at antifungal drugs that are currently on the market, discusses resistance mechanisms and investigates new treatment-enhancing strategies. Combinations of antifungal drugs can increase effectiveness and reduce toxicity. New drug formulations, including nanoparticles are being studied to improve dispersion and reduce adverse effects. Furthermore, commercially marketed prescriptions may become more effective if their chemical makeup is changed. Additionally, novel drugs are being tested more rapidly and precisely using mini-host animal models. These creative methods could expedite the process and enhance patient outcomes. This study notes multiple challenges, such as patient peculiarities, intricate drug interactions and pathogen diversity, while also emphasising the advancements in antifungal therapy. Enhancing efficacy and reducing toxicity requires advancements in diagnosis, treatment and medicine. More studies on emerging fungal infections and antibiotic resistance are needed.
References
Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69:1635–60. doi: 10.1111/jphp.12780.
Revie NM, Iyer KR, Robbins N, Cowen LE. Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol. 2018;45:70–6. doi: 10.1016/j.mib.2018.02.005.
Ahmad S, Bhattacharya D, Kar S, Ranganathan A, Van Kaer L, Das G. Curcumin Nanoparticles Enhance Mycobacterium bovis BCG Vaccine Efficacy by Modulating Host Immune Responses. Infect Immun. 2019;87. doi: 10.1128/IAI.00291-19.
Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12:40–79. doi: 10.1128/CMR.12.1.40.
Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42:4419–31. doi: 10.1128/JCM.42.10.4419-4431.2004.
Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis. 2006;19:571–6. doi: 10.1097/QCO.0b013e3280108e45.
Sprute R, Nacov JA, Neofytos D, Oliverio M, Prattes J, Reinhold I, et al. Antifungal prophylaxis and pre-emptive therapy: When and how? Mol Aspects Med. 2023;92:101190. doi: 10.1016/j.mam.2023.101190.
Kriegl L, Egger M, Boyer J, Hoenigl M, Krause R. New treatment options for critically important WHO fungal priority pathogen. Clin Microbiol Infect. 2025;31(6):922–30. doi: 10.1016/j.cmi.2024.03.006.
Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 2011;75:213–67. doi: 10.1128/MMBR.00045-10.
Lestrade PPA, Meis JF, Melchers WJG, Verweij PE. Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clin Microbiol Infect. 2019;25(7):799–806. doi: 10.1016/j.cmi.2018.11.027.
Fisher MC, Alastruey-Isquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557–71. doi: 10.1038/s41579-022-00720-1.
Hossain CM, Ryan LK, Gera M, Choudhuri S, Lyle N, Ali KA, et al. Antifungals and Drug Resistance. Encyclopedia. 2022;2:1722–37. doi: 10.3390/encyclopedia2040118.
Poissy J, Rouzé A, Cornu M, Nseir S, Sendid B. The changing landscape of invasive fungal infections in ICUs: a need for risk stratification to better target antifungal drugs and the threat of resistance. J Fungi (Basel). 2022;8(9):946. doi: 10.3390/jof8090946.
Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem Rev. 2021;121:3390–411. doi: 10.1021/acs.chemrev.0c00199.
Kolwijck E, van der Hoeven H, de Sévaux RGL, Ten Oever J, Rijstenberg LL, van der Lee HAL, et al. Voriconazole-susceptible and voriconazole-resistant Aspergillus fumigatus coinfection. Am J Respir Crit Care Med. 2016;193:927–9. doi: 10.1164/rccm.201510-2104LE.
Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol. 1999;37:3332–7. doi: 10.1128/JCM.37.10.3332-3337.1999.
Posch W, Blatzer M, Wilflingseder D, Lass-Flörl C. Aspergillus terreus: novel lessons learned on amphotericin B resistance. Med Mycol. 2018;56(Suppl 1):S73–82. doi: 10.1093/mmy/myx119.
Rybak JM, Fortwendel JR, Rogers PD. Emerging threat of triazole-resistant Aspergillus fumigatus. J Antimicrob Chemother. 2018;74:835–47. doi: 10.1093/jac/dky517.
Fakhim H, Badali H, Dannaoui E, Nasirian M, Jahangiri F, Raei M, et al. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species. J Mycol Med. 2022 Nov;32(4):101310. doi: 10.1016/j.mycmed.2022.101310.
Delma FZ, Al-Hatmi AMS, Brüggemann RJM, Melchers WJG, de Hoog S, Verweij PE, et al. Molecular mechanisms of 5-fluorocytosine resistance in yeasts and filamentous fungi. J Fungi (Basel). 2021;7. doi: 10.3390/jof7110909.
Billmyre RB, Applen Clancey S, Li LX, Doering TL, Heitman J. 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nat Commun. 2020;11:1–9. doi: 10.1038/s41467-019-13890-z.
Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, et al; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children; National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J. 2013 Nov;32 Suppl 2(0 2):i-KK4. doi: 10.1097/01.inf.0000437856.09540.11.
Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23. doi: 10.1186/s13054-019-2497-3.
Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65:453–64. doi: 10.1016/j.jinf.2012.08.003.
Brissaud O, Guichoux J, Harambat J, Tandonnet O, Zaoutis T. Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care. 2012;2:1–8. doi: 10.1186/2110-5820-2-6.
Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, Schalekamp S, van der Velden WJFM, Kuiper EJ, et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. Clin Infect Dis. 2019;68:1463–71. doi: 10.1093/cid/ciy859.
Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum Infect Dis. 2018;5. doi: 10.1093/ofid/ofy187.
Peng L, Yang N, Yang Y, Wang Q, Xie X, Sun-Waterhouse D, et al. Atomic cation-vacancy engineering of NiFe-layered double hydroxides for improved activity and stability towards the oxygen evolution reaction. Angew Chem Int Ed. 2021;60:24612–9. doi: 10.1002/anie.202109938.
van Rhijn N, Arikan-Akdagli S, Beardsley J, Bongomin F, Chakrabarti A, Chen SC, et al. Beyond bacteria: the growing threat of antifungal resistance. Lancet. 2024 Sep 14;404(10457):1017-1018. doi: 10.1016/S0140-6736(24)01695-7.
Tsutsuura M, Moriyama H, Kojima N, Misukami Y, Tashiro S, Osa S, et al. The monitoring of vancomycin: a systematic review and meta-analyses of AUC-guided dosing and trough-guided dosing. BMC Infect Dis. 2021;21. doi: 10.1186/s12879-021-05858-6.
Novak AR, Bradley ME, Kiser TH, Mueller SW. Azole-resistant Aspergillus and echinocandin-resistant Candida—what are the treatment options? Curr Fungal Infect Rep. 2020;14:141–52. doi: 10.1007/s12281-020-00379-2.
Ben-Ami R. Systemic antifungal therapy for invasive pulmonary infections. J Fungi (Basel). 2023;9:144. doi: 10.3390/jof9020144.
Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F. Antifungal combinations against Candida species: from bench to bedside. J Fungi (Basel). 2022;8. doi: 10.3390/jof8101077.
Bidaud AL, Botterel F, Chowdhary A, Dannaoui E. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. Antimicrob Agents Chemother. 2019;63. doi: 10.1128/AAC.01393-19.
Campitelli M, Zeineddine N, Samaha G, Maslak S. Combination antifungal therapy: a review of current data. J Clin Med Res. 2017;9:451–6. doi: 10.14740/jocmr2992w.
Cui X, Wang L, Lü Y, Yue C. Development and research progress of anti-drug resistant fungal drugs. J Infect Public Health. 2022;15:986–1000. doi: 10.2147/IDR.S338987.
Lepak AJ, Andes DR. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med. 2014;5. doi: 10.1101/cshperspect.a019653.
Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000;30:653–7. doi: 10.1086/313748.
Houšť J, Spížek J, Havlíček V. Antifungal drugs. Metabolites. 2020;10. doi: 10.3390/metabo10030106.
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi (Basel). 2017;3. doi: 10.3390/jof3040057.
Howard KC, Dennis EK, Watt DS, Garneau-Tsodikova S. A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise. Chem Soc Rev. 2020;49:2426–80. doi: 10.1039/c9cs00556k.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81:1703–29. doi: 10.1007/s40265-021-01611-0.
Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimised treatment of patients. Infection. 2017;45:737–79. doi: 10.1007/s15010-017-1042-z.
Gintjee TJ, Donnelley MA, Thompson GR. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel). 2020;6. doi: 10.3390/jof6010028.
Wiederhold NP. Review of the novel investigational antifungal olorofim. J Fungi (Basel). 2020;6:1–11. doi: 10.3390/jof6030122.
Seyedmousavi S, Chang YC, Law D, Birch M, Rex JH, Kwon-Chung KJ. Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob Agents Chemother. 2019;63. doi: 10.1128/AAC.00129-19.
Denning DW, Bromley MJ. How to bolster the antifungal pipeline. Science. 2015;347:1414–6. doi: 10.1126/science.aaa6097.
Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988;32:1–8. doi: 10.1128/AAC.32.1.1.
Nicola AM, Albuquerque P, Paes HC, Fernandes L, Costa FF, Kioshima ES, et al. Antifungal drugs: new insights in research & development. Pharmacol Ther. 2019;195:21–38. doi: 10.1016/j.pharmthera.2018.10.008.
Cass L, Murray A, Davis A, Woodward K, Albayaty M, Ito K, et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect. 2021;9:e00690. doi: 10.1002/prp2.690.
Hu Y, Liu Z, Zha G, Long S, Sridhara MB, Kumar KS, Rakesh K. Triazole derivatives as potential antifungal agents: A structure-activity relationship (SAR) studies. Process Biochemistry. 2023;135:102–18. doi: 10.1016/j.procbio.2023.10.024.
Sobel JD, Donders G, Degenhardt T, Person K, Curelop S, Ghannoum M, et al. Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis. NEJM Evid. 2022;1. doi: 10.1056/EVIDoa2100055.
Maione A, Mileo A, Pugliese S, Siciliano A, Cirillo L, Carraturo F, et al. VT-1161—a tetrazole for management of mono- and dual-species biofilms. Microorganisms. 2023;11:237. doi: 10.3390/microorganisms11020237.
Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, et al. The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016;60:2528–31. doi: 10.1128/AAC.02770-15.
Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, et al. The fungal Cyp51 inhibitor VT-1129 is efficacious in an experimental model of cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62. doi: 10.1128/AAC.01071-18.
García-García I, Borobia AM. Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs. Expert Opin Drug Metab Toxicol. 2021;17:509–14. doi: 10.1080/17425255.2021.1890715.
Yu Y, Albrecht K, Groll J, Beilhack A. Innovative therapies for invasive fungal infections in preclinical and clinical development. Expert Opin Investig Drugs. 2020;29. doi: 10.1080/13543784.2020.1791819.
Garner LM, Echols CD, Wilson WS. Enteral tube administration of isavuconazole in a pediatric patient. Pediatr Blood Cancer. 2021;68. doi: 10.1002/pbc.29108.
Abu Talib DN, Yong MH, Nasaruddin RA, Che-Hamzah J, Bastion MLC. Chronic endogenous fungal endophthalmitis: diagnostic and treatment challenges: a case report. Medicine (Baltimore). 2021;100:e25459. doi: 10.1097/MD.0000000000025459.
Yang JH, Huang PY, Cheng CW, Shie SS, Lin ZF, Yang LY, et al. Antifungal susceptibility testing with YeastONE is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia. Med Mycol. 2021;59:1114–21. doi: 10.1093/mmy/myab046.
Patel SN, Shah S, Panchal J, Desai C, Upadhya IB, Patel M. Spotlight on the mucormycosis outbreak: a deadly fungal infection that followed the COVID-19 pandemic. Cureus. 2023;15. doi: 10.7759/cureus.35095.
Faraoni D. “Your Guide to Paediatric Anesthesia” by Sims and Johnson: a book review. Open J Anesthesiol. 2012;2:10–10. doi: 10.4236/ojanes.2012.21003.
Brown AD. Identities in Organisation Studies. 2018;40:7–22. doi: 10.1177/0170840618765014.
Xiao Y, Yuan P, Sun Y, Xu Y, Deng X, Wang X, et al. Comparison of topical antifungal agents for oral candidiasis treatment: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;133:282–91. doi: 10.3390/life12111677.
Reddy GKK, Padmavathi AR, Nancharaiah YV. Fungal infections: pathogenesis, antifungals and alternate treatment approaches. Curr Res Microb Sci. 2022;3:100137. doi: 10.1016/j.crmicr.2022.100137.
Zhang Y, Yan Y, Qiu H, Ma Z, Ruan K, Gu J. A mini-review of MXene porous films: preparation, mechanism and application. J Mater Sci Technol. 2022;103:42–9. doi: 10.1016/j.jmst.2021.08.001.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).